NEW YORK--(BUSINESS WIRE)--Praesidian Capital (“Praesidian” or “the Firm”), a leading provider of mezzanine capital for small and mid-sized companies, confirmed today that it has exited successfully its $11.5 million subordinated debt investment in metanexgen, a provider of technology-enabled multichannel marketing solutions for the pharmaceutical and healthcare industry. Praesidian’s exit was in concert with DFW Capital Partners’ sale of the business to Insignia Capital Group. Praesidian made